Advertisement

“Low dose” colestipol in children, adolescents and young adults with familial hypercholesterolemia

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The effect of colestipol on plasma lipids and lipoproteins was studied in children, adolescents and young adults with familial hypercholesterolemia. 0.125 g or 0.25 g/kg body weight were given in randomized sequence for periods of 4 weeks. Total cholesterol was lowered by 13 and 18% with the smaller and larger dose, respectively, and LDL cholesterol lowered by 15% with the smaller and 12% with the larger dose. HDL cholesterol rose by 18 and 32%. LDL composition before and during the study was abnormal due to a markedly reduced triglyceride content. “Low-dose” colestipol is less effective in lowering total plasma and LDL cholesterol than conventional doses but may, due to very few side effects, be advantageously used in cases of familial hypercholesterolemia when plasma cholesterol levels after dietary management are only 15–20% above normal.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fredrickson D.S.
        • Levy R.I.
        Familial hyperlipoproteinemia.
        in: Stanbury J.B. Wyngaarden J.B. Fredrickson D.S. The Metabolic Basis of Inherited Disease. McGraw-Hill, New York, NY1972: 545
        • Stone N.J.
        • Levy R.I.
        • Fredrickson D.S.
        • Verter J.
        Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.
        Circulation. 1974; 49: 476
        • Slack J.
        Risks of ischemic heart disease in familial hyperlipoproteinemic states.
        Lancet. 1969; ii: 1380
        • Segall M.
        • Lloyd J.K.
        • Fosbrooke A.S.
        • et al.
        Treatment of familial hypercholesterolemia in children.
        Lancet. 1970; i: 641
        • Kuo P.T.
        • Hayase K.
        • Costis J.B.
        • Moreyra A.E.
        Use of combined diet and Colestipol in long term Math Eq years) treatment of patients with type II hyperlipoproteinemia.
        Circulation. 1979; 59: 199
        • Thomspon G.R.
        • Myant N.B.
        • Kilpatrick D.
        • Oakley C.M.
        • Raphael M.J.
        • Steiner R.E.
        Assessment of long-term plasma exchange for familial hypercholesterolaemia.
        Brit. Heart J. 1980; 43: 680
        • Schlierf G.
        • Vogel G.
        • Heuck C.C.
        • Oster P.
        • Taetzer H.
        • Schellenberg B.
        Zur Diättherapie der famillären Hypercholesterinämie bei Kindern and Jugendlichen.
        Mschr. Kinderheilk. 1977; 125: 770
        • West R.J.
        • Lloyd J.K.
        Use of cholestyramine in the treatment of children with familial hypercholesterolaemia.
        Arch. Dis. Childh. 1973; 48: 370
        • Mordasini R.
        • Twelsiek F.
        • Oster P.
        • Schellenberger B.
        • Raetzer H.
        • Heuck C.C.
        • Schlierf G.
        Eine vergleichende Untersuchung von Colestyramin and Colestipol bei Kindern and Heranwachsenden mit familiärer Hypercholesterinämie.
        Mschr. Kinderheilk. 1978; 126: 436
        • Witters L.A.
        • Herbert P.N.
        • Shulman R.S.
        • Krauss R.M.
        • Levy R.I.
        Therapeutic failure in familial type II hyperlipoproteinemia.
        Metabolism. 1976; 25: 1017
        • West R.J.
        • Lloyd J.K.
        Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine.
        Lancet. 1980; ii: 873
        • Farah J.R.
        • Kwiterovich Jr., P.O.
        • Neill C.A.
        Dose-effect relation of cholestyramine in children and young adults with familial hypercholesterolaemia.
        Lancet. 1977; i: 59
        • Mordasini R.
        • Twelsiek F.
        • Oster P.
        • Schellenberger B.
        • Raetzer H.
        • Heuck C.C.
        • Schlierf G.
        Abnormal low density lipoproteins in children with familial hypercholesterolemia — Effect of polyanion exchange resins.
        Klin. Wschr. 1978; 56: 805
        • Schlierf G.
        • Oster P.
        • Seidel D.
        • Raetzer H.
        • Schellenberg B.
        • Heuck C.C.
        • Wicklein R.L.
        Tagesprofile von Plasmalipiden and Lipoproteinen bei Patienten mit endogener Hypertriglyzeridämie (Typ IV-Hyperlipoproteinämie).
        Klin. Wschr. 1977; 55: 161
        • Lowry O.H.
        • Roberts N.R.
        • Leiner K.Y.
        • Wu N.
        • Farr L.
        The quantitative histochemistry of brain — Chemical method.
        J. Biol. Chem. 1954; 207: 1
        • Riesen W.
        • Mordasini R.
        • Middelhoff G.
        Quantitation of the two major apoproteins of human high-density lipoproteins by solid phase radioimmunoassay.
        FEBS Lett. 1978; 91: 35
        • Glueck C.J.
        • Fallat R.W.
        • Mellies M.
        • et al.
        Pediatric familial type II hyperlipoproteinemia - Therapy with diet and colestipol resin.
        Pediatrics. 1976; 57: 68
        • Angelin B.
        • Einarsson K.
        Cholestyramine in type IIa hyperlipoproteinemia — Is low-dose treatment feasible.
        Atherosclerosis. 1981; 38: 33
        • Olsson A.G.
        Effekt von Bezafibrat and Clofibrat auf Serum-Lipide and -Lipoproteine von Patienten mit verschiedenen Typen von primärer Hyperlipoproteinämie.
        in: Lipoproteine and Herzinfarkt. Verlag Gerhard Witzstrock, Baden-Baden, Köln, New York1979: 142-144
        • Witztum J.L.
        • Schonfeld G.
        • Weidman S.W.
        • Giese W.E.
        • Dillingham M.A.
        Bile sequestrant therapy alters the composition of low-density and high-density lipoproteins.
        Metabolism. 1979; 28: 221
        • Shepherd J.
        • Packard C.J.
        • Gemmell Morgan H.
        • Third J.L.H.C.
        • Stewart J.M.
        • Veitch Lawrie T.D.
        The effects of cholestryamine on high density lipoprotein metabolism.
        Atherosclerosis. 1979; 33: 433
        • Shepherd J.
        • Packard C.J.
        • Patsch J.R.
        • Gotto Jr., A.M.
        • Taunton O.D.
        Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism.
        J. Clin. Invest. 1979; 63: 858
        • Packard C.J.
        • Stewart J.M.
        • Third J.L.H.C.
        • Gemmell Morgan H.
        • Veitch Lawrie T.D.
        • Shepherd J.
        Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaernia.
        Biochem. Biophys. Acta. 1980; 618: 53